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We collected data during postexposure antimicrobial prophylaxis campaigns and from a prophylaxis pro-
gram evaluation 60 days after start of antimicrobial prophylaxis involving persons from six U.S. sites where
Bacillus anthracis exposures occurred. Adverse events associated with antimicrobial prophylaxis to pre-
vent anthrax were commonly reported, but hospitalizations and serious adverse events as defined by Food
and Drug Administration criteria were rare. Overall adherence during 60 days of antimicrobial prophylaxis
was poor (44%), ranging from 21% of persons exposed in the Morgan postal facility in New York City to
64% of persons exposed at the Brentwood postal facility in Washington, D.C. Adherence was highest
among participants in an investigational new drug protocol to receive additional antibiotics with or without
anthrax vaccine—a likely surrogate for anthrax risk perception. Adherence of <60 days was not consis-
tently associated with adverse events. 
ioterrorist attacks involving the use of Bacillus anthracis
in the fall of 2001 caused 22 cases of cutaneous and inha-
lational anthrax and placed many more persons at risk for this
disease because of workplace exposures (1). The massive pub-
lic health response to these events included an unprecedented
prevention program in which approximately 10,000 persons
across the eastern United States were offered >60 days of pos-
texposure antimicrobial prophylaxis to prevent inhalational
anthrax (2). We describe the exposed population and the provi-
sion of postexposure antimicrobial prophylaxis and analysis
of data for associated adverse events and adherence to
prophylaxis. 
The large-scale use of antimicrobial prophylaxis to prevent
anthrax within the setting of a bioterrorist attack has never
been reported. While ineffective in killing B. anthracis spores,
antibiotics are effective against replicating bacteria that
develop from the spore following germination. After being
inhaled, B. anthracis spores may not germinate immediately
but can remain dormant in the lung and lymphatic system for
weeks to months as they are slowly cleared by the immune
system. As long as spores remain in the body, the risk of ger-
mination, replicating B. anthracis, and clinical anthrax exists.
Based on initial risk assessments and the estimated efficacy of
prophylaxis, antimicrobial postexposure prophylaxis was rec-
ommended during the 2001 anthrax outbreak (3,4). 
Public health and military officials involved in bioterror-
ism preparedness initiatives had identified antimicrobial
agents of choice for this purpose before the 2001 outbreak (5).
Largely through the efforts of these officials, ciprofloxacin and
doxycycline were approved by the Food and Drug Administra-
tion in 2000 and 2001, respectively, for use as antimicrobial
prophylaxis to prevent anthrax and were offered as first-line
agents to exposed persons (6,7). Because of safety concerns
over the use of ciprofloxacin and doxycycline, amoxicillin, to
which B. anthracis is known to be susceptible (8), was offered
as prophylaxis to infants, children, and breastfeeding mothers,
although it is not approved by the Food and Drug Administra-
tion for this indication (2). 
In 2001, as soon as the risk for inhalational anthrax was
identified, announcements were made recommending antimi-
crobial prophylaxis to exposed groups at risk; persons in these
exposed groups were instructed to obtain prophylaxis from a
central distribution point, where antibiotics were supplied
from the National Pharmaceutical Stockpile (9). In December
2001, as vaccine became available, the Centers for Disease
Control and Prevention offered persons who were recom-
mended for 60 days of antimicrobial prophylaxis the opportu-
nity to receive 40 additional days of antibiotics (ciprofloxacin,
doxycycline, or amoxicillin), with or without three doses of
anthrax vaccine, through an investigational new drug (IND)
protocol. Exposed persons were encouraged to consult with
their physicians regarding their individual risk for anthrax and
the benefits of participation in the IND protocol (10).
Methods
Antimicrobial prophylaxis campaigns were centered in six
sites where persons were exposed: American Media, Inc.
employees and visitors in Palm Beach County, Florida; work-
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ers and visitors at the United States Postal Service Trenton
Processing and Distribution Center in Hamilton Township,
New Jersey; employees and visitors at specific parts of the
Hart Senate Office Building in Washington, D.C., as well as
congressional mail workers who handled mail for that site;
employees and visitors at the Brentwood postal facility in
Washington, D.C.; employees working in selected areas of the
Morgan postal facility in New York City; and workers and vis-
itors with exposure to the Wallingford and Seymour postal
facilities in Connecticut (2). Also among the cohort recom-
mended for at least 60 days of antimicrobial prophylaxis were
employees and visitors of the Department of State Annex 32
mailroom facility in Sterling, Virginia, and media workers
associated with cutaneous cases in New York City. Ciprofloxa-
cin was initially provided to all persons unless a specific con-
traindication existed. At the first and second refill visits at the
New York City, New Jersey, Brentwood, and Connecticut sites
(after antimicrobial susceptibility testing results were avail-
able), persons who had been taking ciprofloxacin were encour-
aged to change to doxycycline, provided no contraindications
to doxycycline existed. Persons at the Hart Senate Building
were provided a 60-day supply of ciprofloxacin during the first
week that antimicrobial prophylaxis was distributed. In Flor-
ida, doxycycline was primarily provided at 30-day refill. At all
sites, amoxicillin was provided to pregnant women, breast-
feeding mothers, children, and some persons who had adverse
events associated with ciprofloxacin and doxycycline. 
Data Collection
At each site, we used questionnaires distributed primarily
at 10- and 30-day refill clinics to collect demographic, clinical,
and adherence information. An adverse event was defined as
any self-reported symptom while on antimicrobial prophy-
laxis. Respondents were asked to identify the antimicrobial
agent taken most recently and select symptoms experienced
while taking this agent from a list of possible adverse events.
Early questionnaires used in the first antimicrobial prophylaxis
campaign in Florida focused on the presence of a few specific
symptoms and medical attention sought for adverse events.
Later, in conjunction with 10-day refill clinics, a standardized
questionnaire administered at the New Jersey, New York City,
and Brentwood facilities collected information on a broader
list of adverse events. We did not analyze 10-day New York
City data because a large number of persons completed the
questionnaires who had discontinued postexposure prophy-
laxis as recommended at 10-day follow-up. Modified versions
of this initial questionnaire were used at 30 days at the Florida,
New Jersey, Hart Senate Building, Brentwood, and New York
City facilities. Questionnaires were self-administered in all
sites except New Jersey, where they were administered by a
health-care worker.
Potentially serious adverse events were identified based on
adverse event data collected at 10- and 30-day follow-up
(11,12). Persons who reported seeking medical attention
because of adverse events associated with antimicrobial pro-
phylaxis were further investigated. The definition of a serious
adverse event, based on the Code of Federal Regulations (21
CFR 314.80), was applied to any of the following events asso-
ciated with antimicrobial prophylaxis: death, life-threatening
adverse event, inpatient hospitalization or prolongation of an
existing hospitalization, persistent or substantial disability/
incapacity, congenital anomaly/birth defect, or an important
medical event that requires medical or surgical intervention to
avert one of these outcomes. A clinician interviewed health-
care providers and reviewed medical charts to assess the sever-
ity of the adverse events and determine whether they met the
case definition. The relationship of the adverse event to the
antimicrobial agent used was categorized as definite, probable,
possible, remote, not related, and cannot assess. At day 30, a
standardized data collection form was used. 
Program Evaluation after 60 Days
Beginning in late January 2002, after persons at each site
had completed at least 60 days of antimicrobial prophylaxis,
we evaluated the program for all persons in the exposed
cohort. In our analysis, we included only persons who stated
that they were recommended for at least 60 days of prophy-
laxis during the program evaluation interview. Through brief
telephone interviews using a standardized questionnaire, we
collected information on the ability of exposed persons to
obtain antimicrobial prophylaxis and informational materials,
associated adverse events, and adherence to prophylaxis.
Adherence was defined as self-reported use of antimicrobial
prophylaxis for at least 60 days. Respondents indicating the
presence of adverse events were asked to identify their most
severe or “single most serious” symptom, then identify other
associated symptoms from a list of potential adverse events.
Adverse events identified after the 60-day follow-up could be
associated with overall use of antimicrobial prophylaxis,
meaning respondents were attributing adverse events to one or
more agents used as antimicrobial prophylaxis. Measures of
perceived severity of symptoms, including whether medical
attention was sought for adverse events, were included. Per-
sons reporting nonadherence were asked to give the most
important reason for not taking the antibiotic. We made multi-
ple attempts to reach identified persons; follow-up to deter-
mine characteristics of nonrespondents is ongoing.
Investigation of potentially serious adverse events reported
after the 60-day follow-up is planned in a manner similar to
prior serious adverse event evaluations.  
Data Analysis
Statistical analyses were conducted by using SAS version
8 (SAS Institute, Inc., Cary, NC) statistical software. We used
the c2 test to compare proportions across each of the six sites;
p<0.05 was considered statistically significant.
We conducted two separate analyses for each of the six
sites after 60 days using program evaluation data: one for
nonadherence and one for occurrence of adverse events. The
dependent (outcome) variable for the first analysis wasBIOTERRORISM-RELATED ANTHRAX
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nonadherence (nonadherence [1–59 days of antimicrobial
prophylaxis] versus adherence [>60 days of antimicrobial
prophylaxis]). The dependent (outcome) variable for the
adverse event analysis was self-reported adverse events (a
symptom reported versus no symptom reported). We
excluded persons who reported not obtaining their prophy-
laxis or not taking any of it, as well as those for whom adher-
ence information was not available. We constructed a logistic
regression model for each dependent variable for each of the
six sites. The independent (predictor) variables used in the
logistic models included demographic and clinical variables
from the 60-day program evaluation, including gender, age
group, race, ethnicity, presence of adverse events, and partic-
ipation in the IND protocol. Independent variables were
retained in each of the site-specific models if their estimated
parameters were statistically significant (p<0.05) in any
model for the same dependent variable. We assessed colin-
earity and two-way interactions for all variables in each of
the final multivariable models.  
Results
Approximately 10,000 persons were recommended for at
least 60 days of antimicrobial prophylaxis to prevent inhala-
tional anthrax. The largest number of persons on antimicrobial
prophylaxis was associated with the Brentwood facility
(n=2,743) and the smallest with the Hart Senate Building
(n=600). We completed interviews on 6,178 persons; partici-
pation rates varied by site (Table 1).
Most of the respondents were 40–64 years of age, and 60%
were men. Of 2,444 women, 2% reported being pregnant or
having been pregnant while taking antimicrobial prophylaxis.
Median age was lowest at the Hart Senate Building site and
highest at the Brentwood facility. Approximately 150 persons
were <18 years of age at the start of the antimicrobial prophy-
laxis campaign; the Florida site had the most children (n=88).
The number of children was estimated based on data collected
at 10 and 30 days. Persons <18 years were not interviewed as
part of the program evaluation after 60 days. Forty-one percent
of respondents reported their race as white and 42% as Afri-
can-American, but marked variation existed by site. Members
of the Florida and Hart Senate Building cohorts were primarily
Caucasian, while persons at Brentwood facility were primarily
African-American (Table 2).
Almost all (97%) respondents obtained an initial supply of
antimicrobial prophylaxis. Three percent (n=182) of respon-
dents reported difficulty in obtaining their supply of prophy-
laxis, and of these, most (83%) were able to get 60 days of
prophylaxis. Ten percent of respondents took no antimicrobial
prophylaxis, although they collected an initial supply. This
group and those who never obtained antimicrobial prophylaxis
compose the overall group of 787 respondents who reported
not taking any of their prophylaxis. Forty-eight respondents
did not provide any adherence information. Persons who took
at least one dose of antimicrobial prophylaxis numbered 5,343
(86%); fewer than half of these respondents took only one
agent as antimicrobial prophylaxis. Fifty-nine percent of
respondents taking at least one dose of antimicrobial prophy-
laxis (n=3,156) took two antimicrobial agents as prophylaxis;
56% (n=2,984) took ciprofloxacin for one part of their course
and doxycycline for the rest. Data from 10, 30, and post-60
days show an overall shift in the most recent antimicrobial
agent used from ciprofloxacin (84% at day 10) to doxycycline
(61% at day 60). 
Adverse Events
Of the 5,343 persons who reported taking at least one dose
of antimicrobial prophylaxis, 57% (n=3,032) reported adverse
events during the first 60 days of antimicrobial prophylaxis
use. Reporting of adverse events varied by site, ranging from
42% of respondents at the Connecticut facility to 65% at the
Brentwood facility. Thirty-two percent of respondents with
adverse events reported diarrhea or stomach pain with their
most recent antibiotic, 27% nausea or vomiting, 25% head-
ache, and 22% dizziness. The most commonly reported cate-
gories of symptoms were gastrointestinal (44%, including
nausea or vomiting, diarrhea or stomach pain, heartburn, and
pain with swallowing) and neurologic (33%, including head-
ache, dizziness, lightheadedness, fainting, and seizure). Of the
3,032 persons reporting at least one adverse event, 23% identi-
fied “diarrhea or stomach pain” and 19% “nausea or vomiting”
as their “most serious” symptom. Among persons reporting
adverse events, 14% graded them as severe, 45% as moderate,
and 41% as none/mild. Twenty-six percent of persons with
adverse events reported missing at least 1 day of work because
of symptoms. 
At 10 days, the rate of one or more adverse events among
persons taking ciprofloxacin most recently (45%) did not dif-
fer significantly from that of persons taking doxycycline
Table 1. Response rates for persons recommended for at least 60 
days of postexposure antimicrobial prophylaxis, 2001–2002 
Anthrax 
investigation site
No. of persons 
prescribed 
prophylaxisa
Response rates for prophylaxis 
10 days 
(%)
30 days 
(%)
60 daysb,c 
(%)
Florida 1,082 81 40  78 
New Jersey 1,402 25  64  76 
Hart Senate Building, 
Washington, D.C.
600  n/ad 59 82 
Brentwood facility,
Washington, D.C.
2,743 60 45  62 
New York City 2,259  n/a 23  58 
Connecticut 1,217  n/a  n/a 69 
aWhen determining the number of persons prescribed prophylaxis, we excluded pro-
gram evaluation respondents who indicated that they were not recommended for >60 
days of antimicrobial prophylaxis. This number may vary from estimates using other 
data.
bLists of persons in groups recommended for >60 days of antimicrobial prophylaxis 
were sometimes available only later in the campaign, so denominators may vary slightly 
for each collection period. 
cNo 60-day follow-up available on persons <18 years of age at time of 60-day evalua-
tion.
dn/a, not available.Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1127
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most recently (49%). At day 30, this rate was slightly higher
(77%) among persons taking ciprofloxacin most recently
than persons taking doxycycline most recently (71%,
p<0.01) (Table 3). 
Univariate analysis of factors associated with the presence
of adverse events showed male respondents were less likely to
report adverse events than were female respondents in all sites
except Connecticut. Compared with the youngest age group,
persons who reported adverse events were less likely to be >65
years of age. Persons with adverse events were significantly
more likely to enroll in the IND protocol in the Brentwood
facility (Table 4).
Multivariable analysis also showed that persons reporting
adverse events were less likely to be male in all sites except
Connecticut. At the Hart Senate Building site, persons with
adverse events were less likely to be African-American. At the
Brentwood site, persons with adverse events were more likely
to have enrolled in the IND protocol. 
Medical Attention for Adverse Events 
and Serious Adverse Events
Of 2,907 persons participating in 10-day follow-up, 7%
reported seeking medical attention. Follow-up at 10 days for
serious adverse events in the Florida, New Jersey, and New
York City facilities found no hospitalizations attributable to
antimicrobial prophylaxis in persons seeking medical care for
symptoms consistent with anaphylaxis (difficulty breathing,
rash or itchy skin, throat tightness, or lip and tongue swelling)
(11). Of 3,374 persons participating in 30-day follow-up, 13%
reported seeking medical attention. Of 2,135 persons with fol-
low-up information available at 30 days in the Florida, New
Jersey, New York City, and the Hart Senate Building facilities,
seven persons (0.3%) were found to have had a serious
adverse event, including three persons hospitalized. Ten- and
30-day follow-up data were not available for Connecticut.
Four persons had reactions in which the relationship to antimi-
crobial prophylaxis was judged to be definite or probable,
while the remaining three were classified as not related or
could not assess. Two of four serious adverse events with a
definite or probable relationship to antimicrobial prophylaxis
were characterized by diffuse rash and systemic symptoms;
the remaining two involved swelling of the face and neck. Two
persons were treated as outpatients, one was treated in the
emergency department, and the remaining patient was briefly
hospitalized. All four recovered without sequelae.  
At the post 60-day evaluation, 16% of respondents who
took at least one dose of antimicrobial prophylaxis (n=842)
reported seeking medical care for adverse events caused by
prophylaxis at some time during their 60-day course. Nine per-
cent (n=493) reported that their physician or other health-care
provider advised them to stop taking antibiotics; 54% of these
persons (n=267) reported that the presence of adverse events
was the only reason for the recommendation to discontinue.
Medical follow-up of persons reporting potentially serious
adverse events after 60 days is ongoing. 
Table 2. Demographic data for persons recommended for at least 60 days of postexposure prophylaxis, 2001–2002 
Characteristic
Florida (%)
(n=780)
New Jersey (%)
(n=1,061)
Hart Senate Building, 
Washington, D.C. (%)
(n=485)
Brentwood facility, 
Washington, D.C. (%)
(n=1,694)
New York City (%)
(n=1,315)
Connecticut (%)
(n=843)
Male 62 66  59  58  55  67 
Pregnant 2 1  3  2  2  3 
Caucasian 84 63  76  5  17  63 
African-American 4 23  16  87  45  21 
Median age (yrs) 40 46 34 51 46 44
Age range (yrs) (17–86) (18–77) (17–75) (19–79) (18–78) (17–85)
Table 3. Adverse events at 10 and 30 days, by most recent antimicrobial agent, all sites,a 2001–2002
Adverse events
Day 10 Day 30
Ciprofloxacin (%)
(n=2,446)
Doxycycline (%)
(n=165) p value
Ciprofloxacin (%)
(n=737)
Doxycycline (%)
(n=2,050) p value
>1 adverse event 45  49  0.27 77  71  <0.01
Gastrointestinal symptoms (nausea, vomiting, 
diarrhea, abdominal pain, or heartburn)
26 26  0.89 42  49  <0.01
Fainting, dizziness, light-headedness, or seizuresb 18 11  0.08 23  18  0.01
Rash, hives, or itchy skin 7  7  0.8 14  14  0.6
Joint problemsb 8 7  0.6 25 16  <0.01
aDay 10 data includes the Florida, New Jersey, and Washington, D.C., Brentwood sites; Day 30 data includes the Florida, New Jersey, Washington, D.C., Hart Senate Building , and 
New York City sites.
bDay 10 reports of these symptoms not collected at the Florida site.BIOTERRORISM-RELATED ANTHRAX
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Adherence
Fewer than half of respondents (44%, n=2,712) reported
taking antimicrobial prophylaxis for at least 60 days. Adher-
ence through 60 days was highest at the Brentwood facility
(64%) and lowest at the New York City facility (21%) (Fig-
ure). Of persons who took at least one dose of antimicrobial
prophylaxis, 72% (n=3,873) reported taking their medicine
daily as prescribed, and 19% (n=1,027) reported taking pro-
phylaxis “almost every day.” Eighty-six percent of all respon-
dents were aware of the IND. 
Of 2,631 persons taking at least one dose of antimicrobial
prophylaxis but stopping before 60 days, 43% stated that
adverse events were the most important reason they discontin-
ued prophylaxis, 25% reported perception of a low risk for
anthrax, and 7% identified fear of long-term side effects from
antimicrobial prophylaxis. Of the 172 who never obtained
their prophylaxis, 54% reported perception of a low personal
risk for anthrax as the most important reason for not obtaining
the recommended antimicrobial agent. 
On univariate analysis, in some sites nonadherent respon-
dents were more likely to be African-American, and in other
sites they were more likely to be Hispanic. In New York City,
nonadherent persons were more likely to have sought medical
care and were more likely to have been advised by a health-
care provider to stop taking their antimicrobial prophylaxis. In
all sites, respondents who enrolled in the IND were more
Table 4. Univariate analysis of factors associated with adverse events, post 60-day program evaluation data, 2001–2002a
Variable
Reports of adverse events among persons taking at least one dose of prophylaxis
Florida (n=744)
New Jersey
(n=1,028)
Hart Senate Building, 
Washington, D.C.
(n = 472)
Brentwood facility, 
Washington, D.C.
(n=1,619)
New York City
(n=882)
Connecticut
(n=598)
(%) p value (%) p value (%) p value (%) p value (%) p value (%) p value
Gender
Male 50 <0.01 54 <0.01 54 0.01 60 <0.01 44 <0.01 41 0.53
Female 63 Ref 68 Ref 65 Ref 74 Ref 61 Ref 44 Ref
Age group
17–39 yr  55 Ref 58 Ref 61 Ref 69 Ref 56 Ref 40 Ref
40–64 yr  55 0.99 59 0.75 53 0.10 66 0.38 51 0.20 44 0.37
>65 yr  41 0.19 39 0.03 40 0.34 52 0.04 37 0.04 19 0.10
Race
African-American 54 0.88 61 0.35 46 0.02 67 0.36 52 0.74 36 0.14
All others 55 Ref 58 Ref 61 Ref 63 Ref 51 Ref 44 Ref
Ethnicity
Hispanic 55 1.00 60 0.87 44 0.38 57 0.38 56 0.12 39 0.65
Non-Hispanic 55 Ref 59 Ref 59 Ref 66 Ref 50 Ref 42 Ref
IND enrollment
Yes 48 0.29 61 0.34 68 0.11 71 <0.01 56 0.40 50 0.13
No 56 Ref 57 Ref 57 Ref 63 Ref 51 Ref 41 Ref
Received printed materials about adverse events
No 70 0.03 61 0.73 73 <0.01 78 0.02 29 0.01 53 0.36
Yes 54 Ref 58 Ref 54 Ref 66 Ref 53 Ref 42 Ref
aIND, investigational new drug; Ref, referent.
Figure. Percentage of persons completing at least 60 days of antimicro-
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likely to have been adherent. These associations were statisti-
cally significant in all but one site (Connecticut) (Table 5). 
Six site-specific logistic regression models showed an
adverse event to be associated with <60 days’ adherence in
two sites only (Florida and New York City). Respondents who
enrolled in the IND were more likely to have been adherent in
all sites except Connecticut. Hispanic persons were more
likely to be nonadherent in New Jersey and New York City;
African-American persons were more likely to be nonadherent
in New Jersey and the Hart Senate Building site. Persons in the
40- to 64-year age group were less likely to be nonadherent in
the Florida, New Jersey, Brentwood, and New York City sites
(Table 6).
Discussion
The anthrax outbreak of 2001 represents the first bioterror-
ist attack in the United States using B. anthracis and the first
recorded mass postexposure antimicrobial prophylaxis cam-
paign to prevent inhalational anthrax. Monitoring for adverse
events and adherence during this campaign offers a unique
opportunity to evaluate associated adverse events and adher-
ence to antimicrobial agents in a mass prophylaxis campaign.
Table 5. Univariate analysis of factors associated with nonadherence, post 60-day program evaluation data, 2001–2002a
Variable
Reports of nonadherenceb among persons who took at least one dose of postexposure prophylaxis
Florida (n=744) New Jersey
(n=1,028)
Hart Senate Building, 
Washington, D.C.
(n = 472)
Brentwood facility, 
Washington, D.C.
(n=1,619)
New York City
(n=882)
Connecticut
(n=598)
(%) p value (%) p value (%) p value (%) p value (%) p value (%) p value
Gender
Male 67 0.57 32 <0.01 39 0.71 32 0.27 62 <0.01 68 0.68
Female 69 Ref 47 Ref 41 Ref 34 Ref 77 Ref 70 Ref
Age group
17–39 yr  75 Ref 53 Ref 42 Ref 52 Ref 80 Ref 71 Ref
40–64 yr  61 <0.01 32 <0.01 37 0.33 29 <0.01 67 <0.01 68 0.62
>65 yr  64 0.23 26 <0.01 0 0.08 29 <0.01 33 <0.01 31 <0.01
Race
African-American 82 0.10 44 0.02 53 0.02 33 0.83 72 0.15 72 0.37
All others 67 Ref 35 Ref 38 Ref 32 Ref 67 Ref 68 Ref
Ethnicity
Hispanic 65 0.52 60 <0.01 60 0.19 29 0.67 76 0.03 75 0.30
Non-Hispanic 68 Ref 37 Ref 40 Ref 33 Ref 67 Ref 67 Ref
Adverse events
Yes 75 <0.01 38 0.40 39 0.72 32 0.49 75 <0.01 72 0.13
No 59 Ref 36 Ref 41 Ref 34 Ref 63 Ref 66 Ref
Severity of adverse events
None 64 Ref 37 Ref 45 Ref 33 Ref 63 Ref 65 Ref
Mild 66 0.58 29 0.07 34 0.07 27 0.06 65 0.58 63 0.73
Moderate/severe 72 0.05 44 0.09 43 0.66 36 0.38 79 <0.01 76 0.01
IND enrollment
Yes 46 <0.01 19 <0.01 7 <0.01 16 <0.01 49 <0.01 60 0.08
No 70 Ref 46 Ref 46 Ref 43 Ref 72 Ref 70 Ref
Missed >1 day of work
Yes 72 0.47 40 0.28 33 0.39 32 0.44 77 0.03 74 0.23
No 68 Ref 36 Ref 41 Ref 34 Ref 67 Ref 67 Ref
Sought medical attention
Yes 72 0.36 40 0.42 34 0.18 32 0.58 86 <0.01 65 0.62
No 67 Ref 37 Ref 42 Ref 33 Ref 67 Ref 69 Ref
a IND, investigational new drug.
b1–59 days of postexposure prophylaxis.BIOTERRORISM-RELATED ANTHRAX
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Our data show that the rate of serious adverse events was low,
and adverse event monitoring to date has shown no deaths due
to antimicrobial prophylaxis. Mild adverse events or adverse
events that did not fulfill criteria as serious were common, and
adherence to recommendations for at least 60 days of antimi-
crobial prophylaxis was poor.  
The overall rate of reported adverse events during this cam-
paign was higher than the rate (16.5%) listed on the usage
information provided with ciprofloxacin (13). (The information
provided for doxycycline does not include a rate for adverse
events, so a similar comparison cannot be made with this
agent.) However, comparison of these rates with adverse event
rates associated with antimicrobial prophylaxis must be made
with caution. Adverse events reported in the ciprofloxacin liter-
ature are categorized by their likelihood to be drug related,
while this relationship was assessed only for the small propor-
tion of potentially serious adverse events resulting from antimi-
crobial prophylaxis. Adverse event rates are ideally derived
from data collected under controlled circumstances, including
the presence of a control group, while these data were collected
as part of a response to a public health emergency. Published
adverse event rates among patients taking ciprofloxacin or dox-
ycycline in clinical settings where a similar definition of
adverse event is used provide a closer comparison of adverse
event rates to antimicrobial prophylaxis. A recent published
review of adverse events among patients taking long-term (>30
days) ciprofloxacin in clinical trials found an overall rate of
32% and a rate of gastrointestinal adverse events of 22% (14).
In several small studies, the rate of adverse events among
patients on doxycycline has been shown to be >30% and as
high as 50%, with rates of nausea and vomiting of 31%,
depending on the reporting method used (15–20).
Adverse events to antimicrobial prophylaxis in this event
may be attributed to the known pharmacology of the drugs
taken. However, some portion of the adverse events may also
be ascribed to above-average symptom awareness related to
fear of contracting anthrax. Data from focus groups of exposed
workers support this hypothesis and suggest that self-reports
of stress were frequent (21). Anxiety may have led to symp-
toms or physiologic changes that cannot be explained on the
basis of the known pharmacology of the antimicrobial agents
given but are temporally related to antimicrobial prophylaxis
(22). Regardless of their relation to antimicrobial prophylaxis
or fulfillment of criteria for serious adverse events, high rates
of reported adverse events during this event suggest the need
for a management strategy in addition to monitoring efforts for
future antimicrobial prophylaxis campaigns.  
While overall adverse events rates were high, differences
in rates of adverse events associated with ciprofloxacin com-
pared with those associated with doxycycline were not sub-
Table 6. Factors associated with nonadherence, multivariable analysis, post 60-day data, 2001–2002a
Variable
Participants reporting non-adherence (1–59 days of antimicrobial prophylaxis) among persons taking at least one dose 
Florida (n=744)
OR (95% CI)
New Jersey (n=1,028) 
OR (95% CI)
Hart Senate Building
(n=472) OR 
(95% CI)
Brentwood facility
(n=1,619) OR 
(95% CI)
New York City
(n=882) OR 
(95% CI)
Connecticut
(n=598) OR 
(95% CI)
Gender
Male 1.00 (0.71, 1.41) 0.56 (0.42, 0.76) 0.92 (0.61, 1.38) 0.90 (0.71, 1.13) 0.57 (0.41, 0.79) 0.99 (0.67, 1.46)
Female Referent Referent Referent Referent Referent Referent
Age
17–39 yr Referent Referent Referent Referent Referent Referent
40–64 yr 0.51 (0.36, 0.72) 0.54 (0.40, 0.73) 0.82 (0.53, 1.28) 0.42 (0.32, 0.56) 0.61 (0.41, 0.90) 0.96 (0.64, 1.44)
>65 yr 0.73 (0.28, 1.89) 0.51 (0.23, 1.12) n/a 0.49 (0.24, 1.02) 0.17 (0.08, 0.39) 0.21 (0.07, 0.65)
Race
African-American 1.80 (0.66, 4.92) 1.47 (1.06, 2.05) 1.87 (1.08, 3.25) 0.90 (0.63, 1.28) 1.08 (0.76, 1.52) 1.39 (0.86, 2.24)
All others Referent Referent Referent Referent Referent Referent
Ethnicity
Hispanic 0.78 (0.47, 1.29) 2.42 (1.21, 4.86) 1.58 (0.42, 6.01) 0.62 (0.23, 1.69) 1.57 (1.03, 2.39) 1.42 (0.68, 2.93)
Non-Hispanic Referent Referent Referent Referent Referent Referent
Adverse events
Yes 2.23 (1.61, 3.09) 1.08 (0.82, 1.44) 1.07 (0.71, 1.62) 0.98 (0.77, 1.24) 1.58 (1.16, 2.16) 1.32 (0.92, 1.90)
No Referent Referent Referent Referent Referent Referent
IND enrollment
Yes 0.36 (0.21, 0.64) 0.27 (0.19, 0.38) 0.09 (0.04, 0.24) 0.28 (0.22, 0.36) 0.33 (0.21, 0.52) 0.64 (0.39, 1.05)
No Referent Referent Referent Referent Referent Referent
aOR, odds ratio; CI, confidence interval; IND, investigational new drug.Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1131
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stantial. Many exposed persons were encouraged to change
from ciprofloxacin to doxycycline midway through their
course for reasons not related to adverse events (23). Because
more than half of persons switched from ciprofloxacin to dox-
ycycline or vice versa, attribution of adverse events to a spe-
cific antimicrobial agent is possible only with data collected at
the first and second refill visits; adverse event data collected at
the program evaluation after 60 days reflect overall adverse
events to antimicrobial prophylaxis. Nonetheless, available
agent-specific adverse event data do not show differences
between ciprofloxacin and doxycycline of the magnitude to
warrant preference for one agent over the other in a future anti-
microbial prophylaxis campaign. 
Overall adherence to recommendations to take at least 60
days of antimicrobial prophylaxis was poor. While adherence
to any medical treatment or prophylaxis regimen is essential
for treatment to be successful, adherence to antimicrobial pro-
phylaxis is thought to be particularly important because of the
risk among persons exposed to B. anthracis aerosols for devel-
oping anthrax while spores are slowly cleared from lung and
thoracic lymphatic systems (4). For this analysis we chose pre-
mature discontinuation of antimicrobial prophylaxis as a sur-
rogate for nonadherence, although errors in amount, timing, or
frequency can also constitute nonadherence to a medication
regimen (24). We found the factor most consistently associated
with adherence to be IND participation, which we interpret as
a surrogate for perception of individual risk. Because exposed
persons were asked to consider their risk for anthrax and the
guidance of their health-care provider when making their deci-
sion, IND participation is a marker for an person’s perception
of risk for inhalational anthrax. Some of the respondents who
perceived their risk for anthrax to be high may have been
reluctant to enroll in the IND at the end of the initial 60-day
regimen because of adverse events in response to antimicro-
bial prophylaxis, but our univariate analysis did not demon-
strate that persons with adverse events were less likely to
enroll in the IND protocol. The strong association between
risk perception and adherence to antimicrobial prophylaxis is
consistent with previous studies of a variety of health condi-
tions, which have demonstrated that effective risk communica-
tion based on a close patient-provider relationship is a crucial
determinant of adherence (24–26). 
The presence of adverse events was not consistently asso-
ciated with nonadherence on univariate and multivariable
analysis. When asked directly, a higher proportion of nonad-
herent respondents indicated that the most important reason
for their premature discontinuation was adverse events, rather
than a low personal risk for anthrax (43% vs. 25%, p<0.01). Of
the 1,120 respondents who reported discontinuing antimicro-
bial prophylaxis because of adverse events, at another point in
the interview 16% said that they did not have any adverse
events. Despite the fact that many persons recall discontinuing
antimicrobial prophylaxis because of adverse events, our anal-
ysis showed that risk perception is a stronger and more consis-
tent predictor of adherence across the six exposed cohorts.   
Data on adverse events and adherence must be interpreted
in light of the unusual circumstances of the bioterrorist attacks
of 2001. The difference in clinical and demographic variables
between the six sites prevented us from identifying factors
related to nonadherence or adverse events for the exposed
cohort as a whole. In any future bioterrorist-related B. anthra-
cis exposure, site-specific circumstances of the attack and the
nature of the exposed population must be taken into account
during antimicrobial prophylaxis campaigns. Future adherence
promotion activities should consider existing theoretical mod-
els developed to predict health behaviors, which often stress
the importance of understanding persons’ interest and concern
about their health, their perception of the level of risk to their
health, and education regarding the consequences of the health
problem (27). Adverse event management efforts should help
exposed persons manage adverse events regardless of whether
they are serious or related to antimicrobial prophylaxis or the
terrorism itself. The threat of bioterrorism remains, and we
must incorporate lessons learned from the bioterrorist attacks
of 2001 to prepare for any future attacks. The data presented
here offer public health decision-makers reassurance regarding
the low proportion of serious adverse events to antimicrobial
prophylaxis and guidance regarding the expected level of
adherence during prophylaxis campaigns. Adherence promo-
tion and adverse events management will be essential compo-
nents to providing this potentially life-saving intervention. 
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